Entering text into the input field will update the search result below

Curis leukemia study's monotherapy part gets FDA nod to resume enrollment, others still under partial hold

Aug. 30, 2022 9:00 AM ETCuris, Inc. (CRIS) StockBy: Ravikash Bakolia, SA News Editor

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers

Curis (NASDAQ:CRIS) said the U.S. Food and Drug Administration (FDA) allowed patient enrollment to resume in the monotherapy phase of the TakeAim Leukemia study.

Earlier in August, the FDA had lifted a partial clinical hold on a phase

Recommended For You

More Trending News

About CRIS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CRIS--
Curis, Inc.